|Bid||53.99 x 100|
|Ask||54.01 x 1300|
|Day's Range||52.06 - 54.44|
|52 Week Range||46.01 - 76.48|
|PE Ratio (TTM)||18.84|
|Dividend & Yield||1.56 (2.79%)|
|1y Target Est||N/A|
AstraZeneca plc (ADR)’s failed test was for lung cancer drug Imfinzi. The reason that this matters to BMY stock is because it has a similar drug in testing. Bristol-Myers Squibb Co is testing a combination of Opdivo and Yervoy. Credit Suisse analysts warn that the similarity between the two drug tests may tamper expectations for BMY’s efforts. The bad news for BMY stock came at the same time that it released its earnings report for the second quarter of 2017.
Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen. AstraZeneca's Mystic study, released Thursday, looked at a combination of immune system-boosting drugs to treat non-small cell lung cancer (NSCLC). Bristol-Myers is studying a similar combination of its two top drugs in the same therapy class, Opdivo and Yervoy.